Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2008

01-12-2008 | NON-THEMATIC REVIEW

Caveolin-1 in tumor progression: the good, the bad and the ugly

Authors: Jacky G. Goetz, Patrick Lajoie, Sam M. Wiseman, Ivan R. Nabi

Published in: Cancer and Metastasis Reviews | Issue 4/2008

Login to get access

Abstract

Caveolin-1 (Cav1) is a multifunctional scaffolding protein with multiple binding partners that is associated with cell surface caveolae and the regulation of lipid raft domains. Cav1 regulates multiple cancer-associated processes including cellular transformation, tumor growth, cell migration and metastasis, cell death and survival, multidrug resistance and angiogenesis. However, Cav1 has been reported to impact both positively and negatively on various aspects of tumor progression and while reported to function as a tumor suppressor, it has also been identified as a poor prognostic factor in various human cancers. In this review, we survey the functional roles of Cav1 in cancer and argue that Cav1 function is interdependent on tumor stage and the expression of molecular effectors that impact on its role during tumor progression.
Literature
1.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.PubMed
2.
Yamada, E. (1955). The fine structure of the gall bladder epithelium of the mouse. Journal of Biophysical and Biochemical Cytology, 1(5), 445–458.PubMedCrossRef
3.
Palade, G. E. (1953). Fine structure of blood capillaries. Journal of Applied Physiology, 24, 1424.
4.
Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R., & Anderson, R. G. (1992). Caveolin, a protein component of caveolae membrane coats. Cell, 68(4), 673–82.PubMed
5.
Kurzchalia, T. V., Dupree, P., Parton, R. G., Kellner, R., Virta, H., Lehnert, M., et al. (1992). VIP21, a 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. Journal of Cell Biology, 118(5), 1003–1014.PubMed
6.
Glenney Jr., J. R., & Soppet, D. (1992). Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 89(21), 10517–10521.PubMed
7.
Williams, T. M., & Lisanti, M. P. (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. American Journal of Physiology. Cell Physiology, 288(3), C494–506.PubMed
8.
Navarro, A., Anand-Apte, B., & Parat, M.-O. (2004). A role for caveolae in cell migration. ASEB Journal, 18(15), 1801–1811.
9.
Parton, R. G., & Simons, K. (2007). The multiple faces of caveolae. Nature Reviews. Molecular Cell Biology, 8(3), 185–194.PubMed
10.
Koleske, A. J., Baltimore, D., & Lisanti, M. P. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proceedings of the National Academy of Sciences of the United States of America, 92(5), 1381–1385.PubMed
11.
Capozza, F., Williams, T. M., Schubert, W., McClain, S., Bouzahzah, B., Sotgia, F., et al. (2003). Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. American Journal of Pathology, 162(6), 2029–2039.PubMed
12.
Lee, S. W., Reimer, C. L., Oh, P., Campbell, D. B., & Schnitzer, J. E. (1998). Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 16(11), 1391–1397.PubMed
13.
Engelman, J. A., Zhang, X. L., Galbiati, F., & Lisanti, M. P. (1998). Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Letters, 429(3), 330–336.PubMed
14.
Razani, B., Schlegel, A., Liu, J., & Lisanti, M. P. (2001). Caveolin-1, a putative tumour suppressor gene. Biochemical Society Transactions, 29(Pt 4), 494–499.PubMed
15.
Patel, H. H., Murray, F., & Insel, P. A. (2008). Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annual Review of Pharmacology and Toxicology, 48, 359–391.PubMed
16.
Hayashi, K., Matsuda, S., Machida, K., Yamamoto, T., Fukuda, Y., Nimura, Y., et al. (2001). Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Research, 61(6), 2361–2364.PubMed
17.
Lajoie, P., Partridge, E., Guay, G., Goetz, J. G., Pawling, J., Lagana, A., et al. (2007). Plasma membrane domain organization regulates EGFR signaling in tumor cells. Journal of Cell Biology, 179(2), 341–56.PubMed
18.
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., et al. (2000). Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics, 24(3), 227–35.PubMed
19.
Liscovitch, M., Burgermeister, E., Jain, N., Ravid, D., Shatz, M., & Tencer, L. (2005). Caveolin and cancer: A complex relationship. In M Mattson (Ed.), Membrane microdomain signaling lipid rafts in biology and medicine (pp. 161–190). Totowa, NJ: Human Press.
20.
Fra, A. M., Williamson, E., Simons, K., & Parton, R. G. (1995). De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proceedings of the National Academy of Sciences of the United States of America, 92(19), 8655–8659.PubMed
21.
Williams, T. M., & Lisanti, M. P. (2004). The Caveolin genes: From cell biology to medicine. Annals of Medicine, 36(8), 584–895.PubMed
22.
Scherer, P. E., Lewis, R. Y., Volonte, D., Engelman, J. A., Galbiati, F., Couet, J., et al. (1997). Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. Journal of Biological Chemistry, 272(46), 29337–29346.PubMed
23.
Razani, B. (2002). Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Molecular and Cellular Biology, 22, 2329–2344.PubMed
24.
Lahtinen, U., Honsho, M., Parton, R. G., Simons, K., & Verkade, P. (2003). Involvement of caveolin-2 in caveolar biogenesis in MDCK cells. FEBS Letters, 538(1–3), 85–88.PubMed
25.
Way, M., & Parton, R. G. (1995). M-caveolin, a muscle-specific caveolin-related protein. FEBS Letters, 376(1–2), 108–112.PubMed
26.
Silva, W. I., Maldonado, H. M., Lisanti, M. P., Devellis, J., Chompre, G., Mayol, N., et al. (1999). Identification of caveolae and caveolin in C6 glioma cells. International Journal of Developmental Neuroscience, 17(7), 705–714.PubMed
27.
Galbiati, F., Engelman, J. A., Volonte, D., Zhang, X. L., Minetti, C., Li, M., et al. (2001). Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. Journal of Biological Chemistry, 276(24), 21425–21433.PubMed
28.
Li, S., Seitz, R., & Lisanti, M. P. (1996). Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. Journal of Biological Chemistry, 271(7), 3863–3868.PubMed
29.
Glenney Jr., J. R. (1989). Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. Journal of Biological Chemistry, 264(34), 20163–20166.PubMed
30.
Sanguinetti, A. R., & Mastick, C. C. (2003). c-Abl is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14. Cellular Signalling, 15(3), 289–298.PubMed
31.
Sanguinetti, A. R., Cao, H., & Corley Mastick, C. (2003). Fyn is required for oxidative- and hyperosmotic-stress-induced tyrosine phosphorylation of caveolin-1. Biochemical Journal, 376(Pt 1), 159–168.PubMed
32.
Schlegel, A., Arvan, P., & Lisanti, M. P. (2001). Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. Journal of Biological Chemistry, 276(6), 4398–4408.PubMed
33.
Dietzen, D. J., Hastings, W. R., & Lublin, D. M. (1995). Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. Journal of Biological Chemistry, 270(12), 6838–6842.PubMed
34.
Monier, S., Dietzen, D. J., Hastings, W. R., Lublin, D. M., & Kurzchalia, T. V. (1996). Oligomerization of VIP21-caveolin in vitro is stabilized by long chain fatty acylation or cholesterol. FEBS Letters, 388(2–3), 143–149.PubMed
35.
Couet, J., Li, S., Okamoto, T., Ikezu, T., & Lisanti, M. P. (1997). Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. Journal of Biological Chemistry, 272(10), 6525–6533.PubMed
36.
Garcia-Cardena, G., Martasek, P., Masters, B. S., Skidd, P. M., Couet, J., Li, S., et al. (1997). Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. Journal of Biological Chemistry, 272(41), 25437–25440.PubMed
37.
Li, S., Couet, J., & Lisanti, M. P. (1996). Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. Journal of Biological Chemistry, 271(46), 29182–29190.PubMed
38.
Li, S., Okamoto, T., Chun, M., Sargiacomo, M., Casanova, J. E., Hansen, S. H., et al. (1995). Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. Journal of Biological Chemistry, 270(26), 15693–15701.PubMed
39.
Ostrom, R. S., & Insel, P. A. (2004). The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. British Journal of Pharmacology, 143(2), 235–245.PubMed
40.
Engelman, J. A., Lee, R. J., Karnezis, A., Bearss, D. J., Webster, M., Siegel, P., et al. (1998). Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. Journal of Biological Chemistry, 273(32), 20448–20455.PubMed
41.
Engelman, J. A., Wykoff, C. C., Yasuhara, S., Song, K. S., Okamoto, T., & Lisanti, M. P. (1997). Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. Journal of Biological Chemistry, 272(26), 16374–16781.PubMed
42.
Zhang, X., Ling, M. T., Wang, Q., Lau, C. K., Leung, S. C., Lee, T. K., et al. (2007). Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. Journal of Biological Chemistry, 282(46), 33284–33294.PubMed
43.
Bernatchez, P. N., Bauer, P. M., Yu, J., Prendergast, J. S., He, P., & Sessa, W. C. (2005). Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proceedings of the National Academy of Sciences of the United States of America, 102(3), 761–766.PubMed
44.
Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., et al. (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science, 293(5539), 2449–2452.PubMed
45.
Fernandez, I., Ying, Y., Albanesi, J., & Anderson, R. G. W. (2002). Mechanism of caveolin filament assembly. Proceedings of the National Academy of Sciences of the United States of America, 99(17), 11193–11198.PubMed
46.
Monier, S., Parton, R. G., Vogel, F., Behlke, J., Henske, A., & Kurzchalia, T. V. (1995). VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Molecular Biology of the Cell, 6(7), 911–927.PubMed
47.
Thomsen, P., Roepstorff, K., Stahlhut, M., & van Deurs, B. (2002). Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Molecular Biology of the Cell, 13, 238–250.PubMed
48.
Tagawa, A., Mezzacasa, A., Hayer, A., Longatti, A., Pelkmans, L., & Helenius, A. (2005). Assembly and trafficking of caveolar domains in the cell: Caveolae as stable, cargo-triggered, vesicular transporters. Journal of Cell Biology, 170(5), 769–779.PubMed
49.
Pol, A., Martin, S., Fernandez, M. A., Ingelmo-Torres, M., Ferguson, C., Enrich, C., et al. (2005). Cholesterol and fatty acids regulate dynamic caveolin trafficking through the golgi complex and between the cell surface and lipid bodies. Molecular Biology of the Cell, 16(4), 2091–2105.PubMed
50.
Breuza, L., Corby, S., Arsanto, J. P., Delgrossi, M. H., Scheiffele, P., & Le Bivic, A. (2002). The scaffolding domain of caveolin 2 is responsible for its Golgi localization in Caco-2 cells. Journal of Cell Science, 115(Pt 23), 4457–4467.PubMed
51.
Fernandez, M. A. (2006). Caveolin-1 is essential for liver regeneration. Science, 313, 1628–1632.PubMed
52.
Drab, M. (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in Caveolin-1 gene-disrupted mice. Science, 293, 2449–2452.PubMed
53.
Schubert, W., Frank, P. G., Razani, B., Park, D. S., Chow, C. W., & Lisanti, M. P. (2001). Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. Journal of Biological Chemistry, 276(52), 48619–48622.PubMed
54.
Anderson, H. A., Chen, Y., & Norkin, L. C. (1996). Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae. Molecular Biology of the Cell, 7(11), 1825–1834.PubMed
55.
Pelkmans, L., & Helenius, A. (2002). Endocytosis via caveolae. Traffic, 3(5), 311–320.PubMed
56.
Moriyama, T., Marquez, J. P., Wakatsuki, T., & Sorokin, A. (2007). Caveolar endocytosis is critical for BK virus infection of human renal proximal tubular epithelial cells. Journal of Virology, 81(16), 8552–8562.PubMed
57.
Schnitzer, J. E., Oh, P., & McIntosh, D. P. (1996). Role of GTP hydrolysis in fission of caveolae directly from plasma membranes [published erratum appears in Science 1996 Nov 15;274(5290):1069]. Science, 274(5285), 239–242.PubMed
58.
Minshall, R. D., Tiruppathi, C., Vogel, S. M., Niles, W. D., Gilchrist, A., Hamm, H. E., et al. (2000). Endothelial cell-surface gp60 activates vesicle formation and trafficking via Gi-coupled src kinase signaling pathway. Journal of Cell Biology, 150(5), 1057–1070.PubMed
59.
Parton, R. G., Joggerst, B., & Simons, K. (1994). Regulated internalization of caveolae. Journal of Cell Biology, 127, 1199–1215.PubMed
60.
Pike, L. J. (2006). Rafts defined: A report on the Keystone symposium on lipid rafts and cell function. Journal of Lipid Research, 47(7), 1597–1598.PubMed
61.
Simons, K., & van Meer, G. (1988). Lipid sorting in epithelial cells. Biochemistry, 27(17), 6197–6202.PubMed
62.
Brown, D. (1994). GPI-anchored proteins and detergent-resistant membrane domains. Brazilian Journal of Medical and Biological Research, 27(2), 309–315 (Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica).PubMed
63.
Munro, S. (2003). Lipid rafts: Elusive or illusive? Cell, 115(4), 377–388.PubMed
64.
Sharma, P., Varma, R., Sarasij, R. C., Ira, , Gousset, K., Krishnamoorthy, G., et al. (2004). Nanoscale organization of multiple GPI-anchored proteins in living cell membranes. Cell, 116(4), 577–589.PubMed
65.
Subczynski, W. K., & Kusumi, A. (2003). Dynamics of raft molecules in the cell and artificial membranes: Approaches by pulse EPR spin labeling and single molecule optical microscopy. Biochimica et Biophysica Acta, 1610(2), 231–243.PubMed
66.
Suzuki, K. G., Fujiwara, T. K., Edidin, M., & Kusumi, A. (2007). Dynamic recruitment of phospholipase C gamma at transiently immobilized GPI-anchored receptor clusters induces IP3-Ca2+ signaling: Single-molecule tracking study 2. Journal of Cell Biology, 177(4), 731–742.PubMed
67.
Suzuki, K. G., Fujiwara, T. K., Sanematsu, F., Iino, R., Edidin, M., & Kusumi, A. (2007). GPI-anchored receptor clusters transiently recruit Lyn and G alpha for temporary cluster immobilization and Lyn activation: Single-molecule tracking study 1. Journal of Cell Biology, 177(4), 717–730.PubMed
68.
Parton, R. G., & Hancock, J. F. (2004). Lipid rafts and plasma membrane microorganization: Insights from Ras. Trends in Cell Biology, 14(3), 141–147.PubMed
69.
Murata, M. (1995). VIP21/caveolin is a cholesterol-binding protein. Proceedings of the National Academy of Sciences of the United States of America, 92, 10339–10343.PubMed
70.
Fielding, C. J., Bist, A., & Fielding, P. E. (1997). Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proceedings of the National Academy of Sciences of the United States of America, 94(8), 3753–3758.PubMed
71.
Nabi, I. R., & Le, P. U. (2003). Caveolae/raft-dependent endocytosis. Journal of Cell Biology, 161(4), 673–677.PubMed
72.
Kojic, L., Joshi, B., Lajoie, P., Le, P. U., Leung, S., Cox, M. E., et al. (2007). Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol-3-kinase-dependent in breast carcinoma cells. Journal of Biological Chemistry, 282(40), 29305–29313.PubMed
73.
Le, P. U., Guay, G., Altschuler, Y., & Nabi, I. R. (2002). Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. Journal of Biological Chemistry, 277(5), 3371–3379.PubMed
74.
Sharma, D. K., Brown, J. C., Choudhury, A., Peterson, T. E., Holicky, E., Marks, D. L., et al. (2004). Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Molecular Biology of the Cell, 15(7), 3114–3122.PubMed
75.
Hernandez-Deviez, D. J., Howes, M. T., Laval, S. H., Bushby, K., Hancock, J. F., & Parton, R. G. (2007). Caveolin regulates endocytosis of the muscle repair protein, dysferlin. Journal of Biological Chemistry, 283(10), 6476–6488.PubMed
76.
Hill, M. M., Bastiani, M., Luetterforst, R., Kirkham, M., Kirkham, A., Nixon, S. J., et al. (2008). PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell, 132(1), 113–124.PubMed
77.
Liu, L., & Pilch, P. F. (2008). A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. Journal of Biological Chemistry, 283(7), 4314–4322.PubMed
78.
Head, B. P., & Insel, P. A. (2007). Do caveolins regulate cells by actions outside of caveolae? Trends in Cell Biology, 17(2), 51–57.PubMed
79.
Li, W. P., Liu, P., Pilcher, B. K., & Anderson, R. G. (2001). Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. Journal of Cell Science, 114(Pt 7), 1397–1408.PubMed
80.
Uittenbogaard, A., Ying, Y., & Smart, E. J. (1998). Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. Journal of Biological Chemistry, 273(11), 6525–6532.PubMed
81.
Liu, P., Li, W. P., Machleidt, T., & Anderson, R. G. (1999). Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nature Cell Biology, 1(6), 369–375.PubMed
82.
Sanna, E., Miotti, S., Mazzi, M., De Santis, G., Canevari, S., & Tomassetti, A. (2007). Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. Experimental Cell Research, 313(7), 1307–1317.PubMed
83.
Feng, Y., Venema, V. J., Venema, R. C., Tsai, N., & Caldwell, R. B. (1999). VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochemical and Biophysical Research Communications, 256(1), 192–197.PubMed
84.
Pelkmans, L., Burli, T., Zerial, M., & Helenius, A. (2004). Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell, 118(6), 767–780.PubMed
85.
Lee, H., Volonte, D., Galbiati, F., Iyengar, P., Lublin, D. M., Bregman, D. B., et al. (2000). Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Molecular Endocrinology, 14(11), 1750–1775.PubMed
86.
Beardsley, A., Fang, K., Mertz, H., Castranova, V., Friend, S., & Liu, J. (2005). Loss of Caveolin-1 polarity impedes endothelial cell polarization and directional movement. Journal of Biological Chemistry, 280(5), 3541–3547.PubMed
87.
Hill, M. M., Scherbakov, N., Schiefermeier, N., Baran, J., Hancock, J. F., Huber, L.A., et al. (2007). Reassessing the role of phosphocaveolin-1 in cell adhesion and migration. Traffic, 8, 1695–1705.PubMed
88.
del Pozo, M. A., Balasubramanian, N., Alderson, N. B., Kiosses, W. B., Grande-Garcia, A., Anderson, R. G., et al. (2005). Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nature Cell Biology, 7(9), 901–908.PubMed
89.
Radel, C., & Rizzo, V. (2005). Integrin mechanotransduction stimulates caveolin-1 phosphorylation and recruitment of Csk to mediate actin reorganization. American Journal of Physiology, Heart and Circulatory Physiology, 288(2), H936–945.
90.
Wei, Y., Yang, X., Liu, Q., Wilkins, J. A., & Chapman, H. A. (1999). A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. Journal of Cell Biology, 144(6), 1285–1294.PubMed
91.
Gaus, K., Le Lay, S., Balasubramanian, N., & Schwartz, M. A. (2006). Integrin-mediated adhesion regulates membrane order. Journal of Cell Biology, 174(5), 725–734.PubMed
92.
Goetz, J., Joshi, B., Lajoie, P., Strugnell, S., Scudamore, T., Kojic, L., et al. (2008). Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine phosphorylated caveolin-1. Journal of Cell Biology, 180(6), 1261–1275.PubMed
93.
Mettouchi, A., Klein, S., Guo, W., Lopez-Lago, M., Lemichez, E., Westwick, J. K., et al. (2001). Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Molecular Cell, 8(1), 115–127.PubMed
94.
Wary, K. K., Mariotti, A., Zurzolo, C., & Giancotti, F. G. (1998). A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell, 94(5), 625–634.PubMed
95.
Scherer, P. E., Lisanti, M. P., Baldini, G., Sargiacomo, M., Mastick, C. C., & Lodish, H. F. (1994). Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. Journal of Cell Biology, 127(5), 1233–1243.PubMed
96.
Mikol, D. D., Hong, H. L., Cheng, H. L., & Feldman, E. L. (1999). Caveolin-1 expression in Schwann cells. Glia, 27(1), 39–52.PubMed
97.
Hagiwara, Y., Nishina, Y., Yorifuji, H., & Kikuchi, T. (2002). Immunolocalization of caveolin-1 and caveolin-3 in monkey skeletal, cardiac and uterine smooth muscles. Cell Structure and Function, 27(5), 375–382.PubMed
98.
Kandror, K. V., Stephens, J. M., & Pilch, P. F. (1995). Expression and compartmentalization of caveolin in adipose cells: Coordinate regulation with and structural segregation from GLUT4. Journal of Cell Biology, 129(4), 999–1006.PubMed
99.
Campbell, L., Hollins, A. J., Al-Eid, A., Newman, G. R., von Ruhland, C., & Gumbleton, M. (1999). Caveolin-1 expression and caveolae biogenesis during cell transdifferentiation in lung alveolar epithelial primary cultures. Biochemical and Biophysical Research Communications, 262(3), 744–751.PubMed
100.
Schwab, W., Galbiati, F., Volonte, D., Hempel, U., Wenzel, K. W., Funk, R. H., et al. (1999). Characterisation of caveolins from cartilage: Expression of caveolin-1, -2 and -3 in chondrocytes and in alginate cell culture of the rat tibia. Histochemistry and Cell Biology, 112(1), 41–49.PubMed
101.
Fiucci, G., Ravid, D., Reich, R., & Liscovitch, M. (2002). Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene, 21(15), 2365–2375.PubMed
102.
Suzuki, T., Suzuki, Y., Hanada, K., Hashimoto, A., Redpath, J. L., Stanbridge, E. J., et al. (1998). Reduction of caveolin-1 expression in tumorigenic human cell hybrids. Journal of Biochemistry (Tokyo), 124(2), 383–388.
103.
Razani, B., Altschuler, Y., Zhu, L., Pestell, R. G., Mostov, K. E., & Lisanti, M. P. (2000). Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry, 39(45), 13916–13924.PubMed
104.
Park, D. S., Razani, B., Lasorella, A., Schreiber-Agus, N., Pestell, R. G., Iavarone, A., et al. (2001). Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry, 40(11), 3354–3362.PubMed
105.
Galbiati, F., Volonte, D., Engelman, J. A., Watanabe, G., Burk, R., Pestell, R. G., et al. (1998). Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO Journal, 17(22), 6633–6648.PubMed
106.
Sasai, K., Kakumoto, K., Hanafusa, H., & Akagi, T. (2007). The Ras-MAPK pathway downregulates caveolin-1 in rodent fibroblast but not in human fibroblasts: Implications in the resistance to oncogene-mediated transformation. Oncogene, 26(3), 449–455.PubMed
107.
Tirado, O. M., Mateo-Lozano, S., Villar, J., Dettin, L. E., Llort, A., Gallego, S., et al. (2006). Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing’s sarcoma cells. Cancer Research, 66(20), 9937–9947.PubMed
108.
Cantiani, L., Manara, M. C., Zucchini, C., De Sanctis, P., Zuntini, M., Valvassori, L., et al. (2007). Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Research, 67(16), 7675–7685.PubMed
109.
Zou, W., McDaneld, L., & Smith, L. M. (2003). Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. Anticancer Research, 23(6C), 4581–4586.PubMed
110.
Zhang, X., Shen, P., Coleman, M., Zou, W., Loggie, B. W., Smith, L. M., et al. (2005). Caveolin-1 down-regulation activates estrogen receptor alpha expression and leads to 17beta-estradiol-stimulated mammary tumorigenesis. Anticancer Research, 25(1A), 369–375.PubMed
111.
Williams, T. M., Lee, H., Cheung, M. W., Cohen, A. W., Razani, B., Iyengar, P., et al. (2004). Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: Role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. Journal of Biological Chemistry, 279(23), 24745–24756.PubMed
112.
Williams, T. M., Cheung, M. W., Park, D. S., Razani, B., Cohen, A. W., Muller, W. J., et al. (2003). Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Molecular Biology of the Cell, 14(3), 1027–1042.PubMed
113.
Williams, T. M., Medina, F., Badano, I., Hazan, R. B., Hutchinson, J., Muller, W. J., et al. (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and |dramatically enhances lung metastasis in vivo: Role of cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. Journal of Biological Chemistry, 279(49), 51630–51646.PubMed
114.
Lee, H., Park, D. S., Razani, B., Russell, R. G., Pestell, R. G., & Lisanti, M. P. (2002). Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (−/−) null mice show mammary epithelial cell hyperplasia. American Journal of Pathology, 161(4), 1357–1369.PubMed
115.
Sotgia, F., Williams, T. M., Schubert, W., Medina, F., Minetti, C., Pestell, R. G., et al. (2006). Caveolin-1 deficiency (−/−) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. American Journal of Pathology, 168(1), 292–309.PubMed
116.
Sotgia, F., Schubert, W., Pestell, R. G., & Lisanti, M. P. (2006). Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biology & Therapy, 5(3), 292–297.
117.
Sloan, E. K., Stanley, K. L., & Anderson, R. L. (2004). Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene, 23(47), 7893–7897.PubMed
118.
Hurlstone, A. F., Reid, G., Reeves, J. R., Fraser, J., Strathdee, G., Rahilly, M., et al. (1999). Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene, 18(10), 1881–1890.PubMed
119.
Li, T., Sotgia, F., Vuolo, M. A., Li, M., Yang, W. C., Pestell, R. G., et al. (2006). Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. American Journal of Pathology, 168(6), 1998–2013.PubMed
120.
Han, S. E., Park, K. H., Lee, G., Huh, Y. J., & Min, B. M. (2004). Mutation and aberrant expression of Caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. International Journal of Oncology, 24(2), 435–440.PubMed
121.
Haeusler, J., Hoegel, J., Bachmann, N., Herkommer, K., Paiss, T., Vogel, W., et al. (2005). Association of a CAV-1 haplotype to familial aggressive prostate cancer. The Prostate, 65(2), 171–177.PubMed
122.
Cui, J., Rohr, L. R., Swanson, G., Speights, V. O., Maxwell, T., & Brothman, A. R. (2001). Hypermethylation of the caveolin-1 gene promoter in prostate cancer. The Prostate, 46(3), 249–256.PubMed
123.
Williams, T. M., Hassan, G. S., Li, J., Cohen, A. W., Medina, F., Frank, P. G., et al. (2005). Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. Journal of Biological Chemistry, 280(26), 25134–25145.PubMed
124.
Nasu, Y., Timme, T. L., Yang, G., Bangma, C. H., Li, L., Ren, C., et al. (1998). Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nature Medicine, 4(9), 1062–1064.PubMed
125.
Li, L., Yang, G., Ebara, S., Satoh, T., Nasu, Y., Timme, T. L., et al. (2001). Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Research, 61(11), 4386–4392.PubMed
126.
Satoh, T., Yang, G., Egawa, S., Addai, J., Frolov, A., Kuwao, S., et al. (2003). Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer, 97(5), 1225–1233.PubMed
127.
Yang, G., Truong, L. D., Wheeler, T. M., & Thompson, T. C. (1999). Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Research, 59(22), 5719–5723.PubMed
128.
Suzuoki, M., Miyamoto, M., Kato, K., Hiraoka, K., Oshikiri, T., Nakakubo, Y., et al. (2002). Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. British Journal of Cancer, 87(10), 1140–1144.PubMed
129.
Ando, T., Ishiguro, H., Kimura, M., Mitsui, A., Mori, Y., Sugito, N., et al. (2007). The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncology Reports, 18(3), 601–609.PubMed
130.
Kato, K., Hida, Y., Miyamoto, M., Hashida, H., Shinohara, T., Itoh, T., et al. (2002). Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer, 94(4), 929–933.PubMed
131.
Joshi, B., Strugnell, S., Goetz, J., Kojic, L., Cox, M., Wiseman, S., et al. (2008). Rho/ROCK signaling acts via phospho-caveolin-1 to regulate focal adhesion dynamics and tumor cell migration. Cancer Research, (in press).
132.
Pinilla, S. M., Honrado, E., Hardisson, D., Benitez, J., & Palacios, J. (2006). Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Research and Treatment, 99(1), 85–90.PubMed
133.
Savage, K., Lambros, M. B., Robertson, D., Jones, R. L., Jones, C., Mackay, A., et al. (2007). Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clinical Cancer Research, 13(1), 90–101.PubMed
134.
Joo, H. J., Oh, D. K., Kim, Y. S., Lee, K. B., & Kim, S. J. (2004). Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU International, 93(3), 291–296.PubMed
135.
Phuoc, N. B., Ehara, H., Gotoh, T., Nakano, M., Yokoi, S., Deguchi, T., et al. (2007). Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology, 69(5), 843–848.PubMed
136.
Campbell, L., Gumbleton, M., & Griffiths, D. F. (2003). Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. British Journal of Cancer, 89(10), 1909–1913.PubMed
137.
Barresi, V., Cerasoli, S., Paioli, G., Vitarelli, E., Giuffre, G., Guiducci, G., et al. (2006). Caveolin-1 in meningiomas: Expression and clinico-pathological correlations. Acta Neuropathologica, 112(5), 617–626.PubMed
138.
Ho, C. C., Huang, P. H., Huang, H. Y., Chen, Y. H., Yang, P. C., & Hsu, S. M. (2002). Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. American Journal of Pathology, 161(5), 1647–1656.PubMed
139.
Ho, C. C., Kuo, S. H., Huang, P. H., Huang, H. Y., Yang, C. H., & Yang, P. C. (2007). Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer, 59(1), 105–110.PubMed
140.
Moon, K. C., Lee, G. K., Yoo, S. H., Jeon, Y. K., Chung, J. H., Han, J., et al. (2005). Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Research, 25(6C), 4631–4637.PubMed
141.
Yoo, S. H., Park, Y. S., Kim, H. R., Sung, S. W., Kim, J. H., Shim, Y. S., et al. (2003). Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer, 42(2), 195–202.PubMed
142.
Yang, G., Timme, T. L., Frolov, A., Wheeler, T. M., & Thompson, T. C. (2005). Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer, 103(6), 1186–1194.PubMed
143.
Sagara, Y., Mimori, K., Yoshinaga, K., Tanaka, F., Nishida, K., Ohno, S., et al. (2004). Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. British Journal of Cancer, 91(5), 959–965.PubMed
144.
Sunaga, N., Miyajima, K., Suzuki, M., Sato, M., White, M. A., Ramirez, R. D., et al. (2004). Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Research, 64(12), 4277–4285.PubMed
145.
Wikman, H., Seppanen, J. K., Sarhadi, V. K., Kettunen, E., Salmenkivi, K., Kuosma, E., et al. (2004). Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays. The Journal of Pathology, 203(1), 584–593.PubMed
146.
Wiechen, K., Diatchenko, L., Agoulnik, A., Scharff, K. M., Schober, H., Arlt, K., et al. (2001). Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. American Journal of Pathology, 159(5), 1635–1643.PubMed
147.
Davidson, B., Nesland, J. M., Goldberg, I., Kopolovic, J., Gotlieb, W. H., Bryne, M., et al. (2001). Caveolin-1 expression in advanced-stage ovarian carcinoma—a clinicopathologic study. Gynecologic Oncology, 81(2), 166–171.PubMed
148.
Aldred, M. A., Ginn-Pease, M. E., Morrison, C. D., Popkie, A. P., Gimm, O., Hoang-Vu, C., et al. (2003). Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Research, 63(11), 2864–2871.PubMed
149.
Wiechen, K., Sers, C., Agoulnik, A., Arlt, K., Dietel, M., Schlag, P. M., et al. (2001). Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. American Journal of Pathology, 158(3), 833–839.PubMed
150.
Forget, M. A., Desrosiers, R. R., Del, M., Moumdjian, R., Shedid, D., Berthelet, F., et al. (2002). The expression of Rho proteins decreases with human brain tumor progression: Potential tumor markers. Clinical & Experimental Metastasis, 19(1), 9–15.
151.
Cassoni, P., Senetta, R., Castellano, I., Ortolan, E., Bosco, M., Magnani, I., et al. (2007). Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: Concrete premises for a new reliable diagnostic marker in gliomas. American Journal of Surgical Pathology, 31(5), 760–769.PubMed
152.
Bender, F. C., Reymond, M. A., Bron, C., & Quest, A. F. (2000). Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Research, 60(20), 5870–5878.PubMed
153.
Fine, S. W., Lisanti, M. P., Galbiati, F., & Li, M. (2001). Elevated expression of caveolin-1 in adenocarcinoma of the colon. American Journal of Clinical Pathology, 115(5), 719–724.PubMed
154.
Patlolla, J. M., Swamy, M. V., Raju, J., & Rao, C. V. (2004). Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncology Reports, 11(5), 957–963.PubMed
155.
Carrion, R., Morgan, B. E., Tannenbaum, M., Salup, R., & Morgan, M. B. (2003). Caveolin expression in adult renal tumors. Urologic Oncology, 21(3), 191–196.PubMed
156.
Hung, K. F., Lin, S. C., Liu, C. J., Chang, C. S., Chang, K. W., & Kao, S. Y. (2003). The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. Journal of Oral Pathology & Medicine, 32(8), 461–467.
157.
Pflug, B. R., Reiter, R. E., & Nelson, J. B. (1999). Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. The Prostate, 40(4), 269–273.PubMed
158.
Van den Eynden, G. G., Van Laere, S. J., Van der Auwera, I., Merajver, S. D., Van Marck, E. A., van Dam, P., et al. (2006). Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Research and Treatment, 95(3), 219–228.PubMed
159.
Nestl, A., Von Stein, O. D., Zatloukal, K., Thies, W. G., Herrlich, P., Hofmann, M., et al. (2001). Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Research, 61(4), 1569–1577.PubMed
160.
Zhou, H., Jia, L., Wang, S., Wang, H., Chu, H., Hu, Y., et al. (2006). Divergent expression and roles for caveolin-1 in mouse hepatocarcinoma cell lines with varying invasive ability. Biochemical and Biophysical Research Communications, 345(1), 486–494.PubMed
161.
Tahir, S. A., Yang, G., Ebara, S., Timme, T. L., Satoh, T., Li, L., et al. (2001). Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Research, 61(10), 3882–3885.PubMed
162.
Tsao, S. C., Su, Y. C., Wang, S. L., & Chai, C. Y. (2007). Use of caveolin-1, thyroid transcription factor-1, and cytokeratins 7 and 20 in discriminating between primary and secondary pulmonary adenocarcinoma from breast or colonic origin. Kaohsiung Journal of Medical Sciences, 23(7), 325–331.PubMedCrossRef
163.
Ravid, D., Maor, S., Werner, H., & Liscovitch, M. (2005). Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene, 24(8), 1338–1347.PubMed
164.
Belanger, M. M., Roussel, E., & Couet, J. (2003). Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs, 14(4), 281–287.PubMed
165.
Ravid, D., Maor, S., Werner, H., & Liscovitch, M. (2006). Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Advances in Enzyme Regulation, 46, 163–175.PubMed
166.
Okamoto, T., Schlegel, A., Scherer, P. E., & Lisanti, M. P. (1998). Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. Journal of Biological Chemistry, 273(10), 5419–5422.PubMed
167.
Couet, J., Sargiacomo, M., & Lisanti, M. P. (1997). Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. Journal of Biological Chemistry, 272(48), 30429–30438.PubMed
168.
Yamamoto, M., Toya, Y., Jensen, R. A., & Ishikawa, Y. (1999). Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Experimental Cell Research, 247(2), 380–388.PubMed
169.
Razani, B., Zhang, X. L., Bitzer, M., von Gersdorff, G., Bottinger, E. P., & Lisanti, M. P. (2001). Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. Journal of Biological Chemistry, 276(9), 6727–6738.PubMed
170.
Bilderback, T. R., Gazula, V. R., Lisanti, M. P., & Dobrowsky, R. T. (1999). Caveolin interacts with Trk A and p75(NTR) and regulates neurotrophin signaling pathways. Journal of Biological Chemistry, 274(1), 257–263.PubMed
171.
Matveev, S. V., & Smart, E. J. (2002). Heterologous desensitization of EGF receptors and PDGF receptors by sequestration in caveolae. American Journal of Physiology. Cell Physiology, 282(4), C935–946.PubMed
172.
Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F., & Wrana, J. L. (2003). Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nature Cell Biology, 5(5), 410–421.PubMed
173.
Mineo, C., James, G. L., Smart, E. J., & Anderson, R. G. (1996). Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. Journal of Biological Chemistry, 271(20), 11930–11935.PubMed
174.
Ringerike, T., Blystad, F. D., Levy, F. O., Madshus, I. H., & Stang, E. (2002). Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. Journal of Cell Science, 115(Pt 6), 1331–1340.PubMed
175.
Puri, C., Tosoni, D., Comai, R., Rabellino, A., Segat, D., Caneva, F., et al. (2005). Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Molecular Biology of the Cell, 16(6), 2704–2718.PubMed
176.
Park, W.-Y., Cho, K.-A., Park, J.-S., Kim, D.-I., & Park, S. C. (2001). Attenuation of EGF signaling in Senescent cells by Caveolin. Annals of the New York Academy of Sciences, 928(1), 79–84.PubMedCrossRef
177.
Sigismund, S., Woelk, T., Puri, C., Maspero, E., Tacchetti, C., Transidico, P., et al. (2005). Clathrin-independent endocytosis of ubiquitinated cargos. Proceedings of the National Academy of Sciences of the United States of America, 102(8), 2760–2765.PubMed
178.
Kirkham, M., Fujita, A., Chadda, R., Nixon, S. J., Kurzchalia, T. V., Sharma, D. K., et al. (2005). Ultrastructural identification of uncoated caveolin-independent early endocytic vehicles. Journal of Cell Biology, 168(3), 465–476.PubMed
179.
Lajoie, P., & Nabi, I. R. (2007). Regulation of raft-dependent endocytosis. Journal of Cellular and Molecular Medicine, 11(4), 644–653.PubMed
180.
Hernandez-Deviez, D. J., Howes, M. T., Laval, S. H., Bushby, K., Hancock, J. F., & Parton, R. G. (2008). Caveolin regulates endocytosis of the muscle repair protein, dysferlin. Journal of Biological Chemistry, 283(10), 6476–6488.PubMed
181.
Park, J. S., Park, W. Y., Cho, K. A., Kim, D. I., Jhun, B. H., Kim, S. R., et al. (2001). Down-regulation of amphiphysin-1 is responsible for reduced receptor-mediated endocytosis in the senescent cells. FASEB Journal, 15(9), 1625–1627.PubMed
182.
Abulrob, A., Giuseppin, S., Andrade, M. F., McDermid, A., Moreno, M., & Stanimirovic, D. (2004). Interactions of EGFR and caveolin-1 in human glioblastoma cells: Evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene, 23(41), 6967–6979.PubMed
183.
Lu, Z., Ghosh, S., Wang, Z., & Hunter, T. (2003). Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell, 4(6), 499–515.PubMed
184.
Kim, Y. N., Dam, P., & Bertics, P. J. (2002). Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: Dependence on ErbB1 expression and Src activation. Experimental Cell Research, 280(1), 134–147.PubMed
185.
Kim, Y. N., Wiepz, G. J., Guadarrama, A. G., & Bertics, P. J. (2000). Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. Journal of Biological Chemistry, 275(11), 7481–7491.PubMed
186.
Zhang, B., Peng, F., Wu, D., Ingram, A. J., Gao, B., & Krepinsky, J. C. (2007). Caveolin-1 phosphorylation is required for stretch-induced EGFR and Akt activation in mesangial cells. Cellular Signalling, 19(8), 1690–1700.PubMed
187.
Jiang, L. Q., Feng, X., Zhou, W., Knyazev, P. G., Ullrich, A., & Chen, Z. (2006). Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation. Oncogene, 25(40), 5495–5506.PubMed
188.
Wang, X. Q., Sun, P., & Paller, A. S. (2002). Ganglioside induces caveolin-1 redistribution and interaction with the epidermal growth factor receptor. Journal of Biological Chemistry, 277(49), 47028–47034.PubMed
189.
Olivares-Reyes, J. A., Shah, B. H., Hernandez-Aranda, J., Garcia-Caballero, A., Farshori, M. P., Garcia-Sainz, J. A., et al. (2005). Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. Molecular Pharmacology, 68(2), 356–364.PubMed
190.
Ushio-Fukai, M., Hilenski, L., Santanam, N., Becker, P. L., Ma, Y., Griendling, K. K., et al. (2001). Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: Role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. Journal of Biological Chemistry, 276(51), 48269–48275.PubMed
191.
Yamamoto, M., Toya, Y., Schwencke, C., Lisanti, M. P., Myers Jr., M. G., & Ishikawa, Y. (1998). Caveolin is an activator of insulin receptor signaling. Journal of Biological Chemistry, 273(41), 26962–26968.PubMed
192.
Wharton, J., Meshulam, T., Vallega, G., & Pilch, P. (2005). Dissociation of insulin receptor expression and signaling from caveolin-1 expression. Journal of Biological Chemistry, 280(14), 13483–13486.PubMed
193.
Oh, Y. S., Cho, K. A., Ryu, S. J., Khil, L. Y., Jun, H. S., Yoon, J. W., et al. (2006). Regulation of insulin response in skeletal muscle cell by caveolin status. Journal of Cellular Biochemistry, 99(3), 747–758.PubMed
194.
Lu, X., Kambe, F., Cao, X., Yoshida, T., Ohmori, S., Murakami, K., et al. (2006). DHCR24-knockout embryonic fibroblasts are susceptible to serum withdrawal-induced apoptosis because of dysfunction of caveolae and insulin-Akt-Bad signaling. Endocrinology, 147(6), 3123–3132.PubMed
195.
Mastick, C. C., Brady, M. J., & Saltiel, A. R. (1995). Insulin stimulates the tyrosine phosphorylation of caveolin. Journal of Cell Biology, 129(6), 1523–1531.PubMed
196.
Mastick, C. C., & Saltiel, A. R. (1997). Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. Journal of Biological Chemistry, 272(33), 20706–20714.PubMed
197.
Kimura, A., Mora, S., Shigematsu, S., Pessin, J. E., & Saltiel, A. R. (2002). The insulin receptor catalyzes the tyrosine phosphorylation of caveolin-1. Journal of Biological Chemistry, 277(33), 30153–30158.PubMed
198.
Cao, H., Courchesne, W. E., & Mastick, C. C. (2002). A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: Recruitment of C-terminal Src kinase. Journal of Biological Chemistry, 277(11), 8771–8774.PubMed
199.
Cohen, A. W., Razani, B., Wang, X. B., Combs, T. P., Williams, T. M., Scherer, P. E., et al. (2003). Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. American Journal of Physiology. Cell Physiology, 285(1), C222–235.PubMed
200.
Gustavsson, J., Parpal, S., Karlsson, M., Ramsing, C., Thorn, H., Borg, M., et al. (1999). Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB Journal, 13(14), 1961–1971.PubMed
201.
Karlsson, M., Thorn, H., Danielsson, A., Stenkula, K. G., Ost, A., Gustavsson, J., et al. (2004). Colocalization of insulin receptor and insulin receptor substrate-1 to caveolae in primary human adipocytes. Cholesterol depletion blocks insulin signalling for metabolic and mitogenic control. European Journal of Biochemistry, 271(12), 2471–2479.PubMed
202.
Souto, R. P., Vallega, G., Wharton, J., Vinten, J., Tranum-Jensen, J., & Pilch, P. F. (2003). Immunopurification and characterization of rat adipocyte caveolae suggest their dissociation from insulin signaling. Journal of Biological Chemistry, 278(20), 18321–18329.PubMed
203.
Nystrom, F. H., Chen, H., Cong, L. N., Li, Y., & Quon, M. J. (1999). Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Molecular Endocrinology, 13(12), 2013–2024.PubMed
204.
Kabayama, K., Sato, T., Saito, K., Loberto, N., Prinetti, A., Sonnino, S., et al. (2007). Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 104(34), 13678–13683.PubMed
205.
Bauer, P. M. (2005). Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 102, 204–209.PubMed
206.
Gonzalez, E., Nagiel, A., Lin, A. J., Golan, D. E., & Michel, T. (2004). Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. Journal of Biological Chemistry, 279(39), 40659–40669.PubMed
207.
Razani, B., Engelman, J. A., Wang, X. B., Schubert, W., Zhang, X. L., Marks, C. B., et al. (2001). Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. Journal of Biological Chemistry, 276(41), 38121–38138.PubMed
208.
Galbiati, F., Volonte, D., Liu, J., Capozza, F., Frank, P. G., Zhu, L., et al. (2001). Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Molecular Biology of the Cell, 12(8), 2229–2244.PubMed
209.
Volonte, D., Zhang, K., Lisanti, M. P., & Galbiati, F. (2002). Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Molecular Biology of the Cell, 13(7), 2502–2517.PubMed
210.
Cho, K. A., Ryu, S. J., Park, J. S., Jang, I. S., Ahn, J. S., Kim, K. T., et al. (2003). Senescent phenotype can be reversed by reduction of caveolin status. Journal of Biological Chemistry, 278(30), 27789–27795.PubMed
211.
Scheel, J., Srinivasan, J., Honnert, U., Henske, A., & Kurzchalia, T. V. (1999). Involvement of caveolin-1 in meiotic cell-cycle progression in Caenorhabditis elegans. Nature Cell Biology, 1(2), 127–129.PubMed
212.
Hulit, J., Bash, T., Fu, M., Galbiati, F., Albanese, C., Sage, D. R., et al. (2000). The cyclin D1 gene is transcriptionally repressed by caveolin-1. Journal of Biological Chemistry, 275(28), 21203–21209.PubMed
213.
Galbiati, F., Volonte, D., Brown, A. M., Weinstein, D. E., Ben-Ze’ev, A., Pestell, R. G., et al. (2000). Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. Journal of Biological Chemistry, 275(30), 23368–23377.PubMed
214.
Liu, P., Ying, Y., & Anderson, R. G. (1997). Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. Proceedings of the National Academy of Sciences of the United States of America, 94(25), 13666–13670.PubMed
215.
Liu, P., Ying, Y., Ko, Y. G., & Anderson, R. G. (1996). Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. Journal of Biological Chemistry, 271(17), 10299–10303.PubMed
216.
Smart, E. J., Ying, Y. S., Mineo, C., & Anderson, R. G. (1995). A detergent-free method for purifying caveolae membrane from tissue culture cells. Proceedings of the National Academy of Sciences of the United States of America, 92(22), 10104–10108.PubMed
217.
Zhang, W., Razani, B., Altschuler, Y., Bouzahzah, B., Mostov, K. E., Pestell, R. G., et al. (2000). Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. Journal of Biological Chemistry, 275(27), 20717–20725.PubMed
218.
Engelman, J. A., Chu, C., Lin, A., Jo, H., Ikezu, T., Okamoto, T., et al. (1998). Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Letters, 428(3), 205–211.PubMed
219.
Cohen, A. W., Park, D. S., Woodman, S. E., Williams, T. M., Chandra, M., Shirani, J., et al. (2003). Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. American Journal of Physiology. Cell Physiology, 284(2), C457–474.PubMed
220.
Engelman, J. A., Zhang, X. L., Razani, B., Pestell, R. G., & Lisanti, M. P. (1999). p42/44 MAP kinase-dependent and –independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. Journal of Biological Chemistry, 274(45), 32333–32341.PubMed
221.
Liu, P., & Anderson, R. G. (1995). Compartmentalized production of ceramide at the cell surface. Journal of Biological Chemistry, 270(45), 27179–27185.PubMed
222.
Bilderback, T. R., Grigsby, R. J., & Dobrowsky, R. T. (1997). Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae. Journal of Biological Chemistry, 272(16), 10922–10927.PubMed
223.
Veldman, R. J., Maestre, N., Aduib, O. M., Medin, J. A., Salvayre, R., & Levade, T. (2001). A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: Potential implications in tumour necrosis factor signalling. Biochemical Journal, 355(Pt 3), 859–868.PubMed
224.
Ko, Y. G., Lee, J. S., Kang, Y. S., Ahn, J. H., & Seo, J. S. (1999). TNF-alpha-mediated apoptosis is initiated in caveolae-like domains. Journal of Immunology, 162(12), 7217–7223.
225.
Czarny, M., Liu, J., Oh, P., & Schnitzer, J. E. (2003). Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide. Journal of Biological Chemistry, 278(7), 4424–4430.PubMed
226.
Czarny, M., & Schnitzer, J. E. (2004). Neutral sphingomyelinase inhibitor scyphostatin prevents and ceramide mimics mechanotransduction in vascular endothelium. American Journal of Physiology Heart and Circulatory Physiology, 287(3), H1344–1352.PubMed
227.
Zundel, W., Swiersz, L. M., & Giaccia, A. (2000). Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Molecular and Cellular Biology, 20(5), 1507–1514.PubMed
228.
Zhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005). Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. Journal of Clinical Investigation, 115(4), 959–968.PubMed
229.
Liu, J., Lee, P., Galbiati, F., Kitsis, R. N., & Lisanti, M. P. (2001). Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. American Journal of Physiology. Cell Physiology, 280(4), C823–835.PubMed
230.
Shack, S., Wang, X. T., Kokkonen, G. C., Gorospe, M., Longo, D. L., & Holbrook, N. J. (2003). Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Molecular and Cellular Biology, 23(7), 2407–2414.PubMed
231.
Lin, M. I., Yu, J., Murata, T., & Sessa, W. C. (2007). Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Research, 67(6), 2849–2856.PubMed
232.
Shajahan, A. N., Wang, A., Decker, M., Minshall, R. D., Liu, M. C., & Clarke, R. (2007). Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. Journal of Biological Chemistry, 282(8), 5934–5943.PubMed
233.
Podar, K., Tai, Y. T., Cole, C. E., Hideshima, T., Sattler, M., Hamblin, A., et al. (2003). Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. Journal of Biological Chemistry, 278(8), 5794–5801.PubMed
234.
Li, L., Ren, C. H., Tahir, S. A., Ren, C., & Thompson, T. C. (2003). Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Molecular and Cellular Biology, 23(24), 9389–9404.PubMed
235.
Ayala, G. E., Dai, H., Tahir, S. A., Li, R., Timme, T., Ittmann, M., et al. (2006). Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Research, 66(10), 5159–5164.PubMed
236.
Timme, T. L., Goltsov, A., Tahir, S., Li, L., Wang, J., Ren, C., et al. (2000). Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene, 19(29), 3256–3265.PubMed
237.
Glait, C., Tencer, L., Ravid, D., Sarfstein, R., Liscovitch, M., & Werner, H. (2006). Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Experimental Cell Research, 312(19), 3899–3908.PubMed
238.
Shaul, P. W., & Anderson, R. G. (1998). Role of plasmalemmal caveolae in signal transduction. American Journal of Physiology, 275(5 Pt 1), L843–851.PubMed
239.
Isshiki, M., Ando, J., Korenaga, R., Kogo, H., Fujimoto, T., Fujita, T., et al. (1998). Endothelial Ca2+ waves preferentially originate at specific loci in caveolin-rich cell edges. Proceedings of the National Academy of Sciences of the United States of America, 95(9), 5009–5014.PubMed
240.
Isshiki, M., Ando, J., Yamamoto, K., Fujita, T., Ying, Y., & Anderson, R. G. (2002). Sites of Ca(2+) wave initiation move with caveolae to the trailing edge of migrating cells. Journal of Cell Science, 115(Pt 3), 475–484.PubMed
241.
Parat, M. O., Anand-Apte, B., & Fox, P. L. (2003). Differential caveolin-1 polarization in endothelial cells during migration in two and three dimensions. Molecular Biology of the Cell, 14(8), 3156–3168.PubMed
242.
Lentini, D., Guzzi, F., Pimpinelli, F., Zaninetti, R., Cassetti, A., Coco, S., et al. (2007). Polarization of caveolins and caveolae during migration of immortalized neurons. Journal of Neurochemistry, 104(2), 514–523.
243.
Santilman, V., Baran, J., Anand-Apte, B., Evans, R. M., & Parat, M. O. (2007). Caveolin-1 polarization in transmigrating endothelial cells requires binding to intermediate filaments. Angiogenesis, 10(4), 297–305.PubMed
244.
Sun, X. H., Flynn, D. C., Castranova, V., Millecchia, L. L., Beardsley, A. R., & Liu, J. (2007). Identification of a novel domain at the N terminus of caveolin-1 that controls rear polarization of the protein and caveolae formation. Journal of Biological Chemistry, 282(10), 7232–7241.PubMed
245.
Zaidel-Bar, R., Itzkovitz, S., Ma’ayan, A., Iyengar, R., & Geiger, B. (2007). Functional atlas of the integrin adhesome. Nature Cell Biology, 9(8), 858–867.PubMed
246.
Radel, C., Carlile-Klusacek, M., & Rizzo, V. (2007). Participation of caveolae in beta1 integrin-mediated mechanotransduction. Biochemical and Biophysical Research Communications, 358(2), 626–631.PubMed
247.
Cordes, N., Frick, S., Brunner, T. B., Pilarsky, C., Grutzmann, R., Sipos, B., et al. (2007). Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene, 26(48), 6851–6862.PubMed
248.
Swaney, J. S., Patel, H. H., Yokoyama, U., Head, B. P., Roth, D. M., & Insel, P. A. (2006). Focal adhesions in (myo)fibroblasts scaffold adenylyl cyclase with phosphorylated caveolin. Journal of Biological Chemistry, 281(25), 17173–17179.PubMed
249.
Grande-Garcia, A., Echarri, A., de Rooij, J., Alderson, N. B., Waterman-Storer, C. M., Valdivielso, J. M., et al. (2007). Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. Journal of Cell Biology, 177(4), 683–694.PubMed
250.
Ikeda, S., Ushio-Fukai, M., Zuo, L., Tojo, T., Dikalov, S., Patrushev, N. A., et al. (2005). Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis. Circulation Research, 96(4), 467–475.PubMed
251.
Podar, K., Shringarpure, R., Tai, Y. T., Simoncini, M., Sattler, M., Ishitsuka, K., et al. (2004). Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Research, 64(20), 7500–7506.PubMed
252.
Bailey, K. M., & Liu, J. (2008). Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. Journal of Biological Chemistry, M709329200.
253.
Lin, M., DiVito, M. M., Merajver, S. D., Boyanapalli, M., & van Golen, K. L. (2005). Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. Molecular Cancer, 4(1), 21.PubMed
254.
Orlichenko, L., Huang, B., Krueger, E., & McNiven, M. A. (2006). Epithelial growth factor-induced phosphorylation of caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. Journal of Biological Chemistry, 281(8), 4570–4579.PubMed
255.
Aoki, T., Nomura, R., & Fujimoto, T. (1999). Tyrosine phosphorylation of caveolin-1 in the endothelium. Experimental Cell Research, 253(2), 629–636.PubMed
256.
del Pozo, M. A., Alderson, N. B., Kiosses, W. B., Chiang, H. H., Anderson, R. G., & Schwartz, M. A. (2004). Integrins regulate Rac targeting by internalization of membrane domains. Science, 303(5659), 839–842.PubMed
257.
Del Pozo, M. A., & Schwartz, M. A. (2007). Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends in Cell Biology, 17(5), 246–250.PubMed
258.
Demetriou, M., Granovsky, M., Quaggin, S., & Dennis, J. W. (2001). Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature, 409(6821), 733–739.PubMed
259.
Partridge, E. A., Le Roy, C., Di Guglielmo, G. M., Pawling, J., Cheung, P., Granovsky, M., et al. (2004). Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science, 306(5693), 120–124.PubMed
260.
Lau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., et al. (2007). Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell, 129(1), 123–134.PubMed
261.
Dennis, J. W., Pawling, J., Cheung, P., Partridge, E., & Demetriou, M. (2002). UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6 N-acetylglucosaminyltransferase V (Mgat5) deficient mice. Biochimica et Biophysica Acta, 1573(3), 414–422.PubMed
262.
Takenaka, Y., Fukumori, T., & Raz, A. (2004). Galectin-3 and metastasis. Glycoconjugate Journal, 19(7–9), 543–549.PubMed
263.
Nangia-Makker, P., Hogan, V., Honjo, Y., Baccarini, S., Tait, L., Bresalier, R., et al. (2002). Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus Pectin. Journal of the National Cancer Institute, 94(24), 1854–1862.PubMed
264.
Pienta, K. J., Naik, H., Akhtar, A., Yamazaki, K., Replogle, T. S., Lehr, J., et al. (1995). Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. Journal of the National Cancer Institute, 87(5), 348–353.PubMed
265.
Dewever, J., Frerart, F., Bouzin, C., Baudelet, C., Ansiaux, R., Sonveaux, P., et al. (2007). Caveolin-1 is critical for the maturation of tumor blood vessels through the regulation of both endothelial tube formation and mural cell recruitment. American Journal of Pathology, 171(5), 1619–1628.PubMed
266.
Yang, G., Addai, J., Wheeler, T. M., Frolov, A., Miles, B. J., Kadmon, D., et al. (2007). Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Human Pathology, 38(11), 1688–1695.PubMed
267.
Bartz, R., Zhou, J., Hsieh, J. T., Ying, Y., Li, W., & Liu, P. (2007). Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. International Journal of Cancer, 122(3), 520–525.
268.
Brouet, A., DeWever, J., Martinive, P., Havaux, X., Bouzin, C., Sonveaux, P., et al. (2005). Antitumor effects of in vivo caveolin gene delivery are associated with the inhibition of the proangiogenic and vasodilatory effects of nitric oxide. FASEB Journal, 19(6), 602–604.PubMed
269.
Oh, P., Borgstrom, P., Witkiewicz, H., Li, Y., Borgstrom, B. J., Chrastina, A., et al. (2007). Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nature Biotechnology, 25(3), 327–337.PubMed
270.
Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., et al. (2004). Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature, 429(6992), 629–635.PubMed
271.
Gratton, J. P., Lin, M. I., Yu, J., Weiss, E. D., Jiang, Z. L., Fairchild, T. A., et al. (2003). Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell, 4(1), 31–39.PubMed
272.
Podar, K., & Anderson, K. C. (2006). Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Letters, 233(1), 10–15.PubMed
273.
Pramudji, C., Shimura, S., Ebara, S., Yang, G., Wang, J., Ren, C., et al. (2001). In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clinical Cancer Research, 7(12), 4272–4279.PubMed
Metadata
Title
Caveolin-1 in tumor progression: the good, the bad and the ugly
Authors
Jacky G. Goetz
Patrick Lajoie
Sam M. Wiseman
Ivan R. Nabi
Publication date
01-12-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9160-9

Other articles of this Issue 4/2008

Cancer and Metastasis Reviews 4/2008 Go to the issue

OriginalPaper

Imaging of tumor glucose utilization with positron emission tomography

OriginalPaper

Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children

OriginalPaper

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

EditorialNotes

Preface-imaging in cancer

OriginalPaper

Imaging of integrin αvβ3 expression

NON-THEMATIC REVIEW

Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits